SITC Archive Library

On October 6, 2021, leading experts in cancer immunotherapy discussed the latest advances in cancer immunotherapy emerging from ASCO 2021. The recorded webinar and presentation slides are available below.

Webinar Faculty:

• Moderator: Evan J. Lipson, MD – Johns Hopkins University
• Presenters:
  • Ulka Vaishampayan, MD – University of Michigan
  • Jarushka Naidoo, MBBCH, MHS – Beaumont RCSI Cancer Centre Dublin
  • Matthew Frigault, MD, MSc - Massachusetts General Hospital

Featured Presentations:

• Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study. - Presenter: Ulka Vaishampayan, MD
•  First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. - Presenter: Jarushka Naidoo, MBBCH, MHS
• Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1. - Presenter: Matthew Frigault, MD, MSc

Please note that the on-demand webinar is not available for continuing education credits.